Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- (-) Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- (-) Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 172 Results
Insurance Switching and the Mismatch Between the Costs and Benefits of New Technologies
The peer-reviewed study examined the disconnect between the short-term budget impact of a treatment and its downstream effects on payers and society.
Why We Need A Serious Conversation About Health Spending
The government released its annual assessment on health spending in 2016 and the overall spending number came in at $3.3 trillion, up 4.3 percent from 2015. We know the easy fixes aren’t up to the…
NPC in Health Affairs Blog: It’s Time for a Serious Conversation About Health Care Spending
In a blog published today in Health Affairs, National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, noted that a serious conversation among all health care stakeholders is…
Where Are They Now: Checking In With Former NPC Fellow Chuck Shih
Chuck Shih, PhD, MHS, currently Senior Officer, Drug Spending at Pew Charitable Trusts, was the 2013-2015 NPC Health Policy Fellow as part of a partnership with the George Washington University…
When and How is Real-World Evidence Useful in Payer Decision-Making?
Research published in Value in Health from the National Pharmaceutical Council and the University of Arizona School of Pharmacy sheds more light on how real-world evidence is used in decision-making…
Real-World Evidence: Useful in the Real World of United States Payer Decision-Making? How? When? And What Studies?
Research published in Value in Health on real-world evidence provides a deeper understanding of when and how managed care organizations use RWE in decision-making, and how to increase its use.
What’s Contributing to Unnecessary Health Spending?
Reducing low-value care—health care that is cost-inefficient and clinically ineffective—remains a front burner issue for health care stakeholders. It hasn’t been easy to root out or measure low-value…
Understanding Real-World Evidence
NPC explores the benefits and challenges with the use of real-world evidence in this first article in a series on this topic.
Information Wanted: Finding the Balance in Pharmaceutical Evidence Exchange With Payers and Providers
Payers and providers were surveyed to understand the type of health care economic information (HCEI) they desire and value in the current and future health care environment, as well as the potential…
Making Real-World Evidence “Real” for Patients
As real-world evidence (RWE) becomes more broadly used in health care, it’s important to ensure that patients understand what RWE is, determine and address the questions and concerns patients…
Value Depends on Real-World Evidence
In his latest commentary for the American Journal of Pharmacy Benefits, NPC President Dan Leonard examines the challenges with developing, analyzing, using and communicating real-world evidence in…
An Opportunity to Thoughtfully and Holistically Address Health Care Spending
The Medicare Trustees Annual Report issued last week was a mix of positive news and a stark reminder that we need to find thoughtful solutions to ensure that the Medicare program will remain solvent…
Asking the Right Questions About Our Health Care System Costs
With health news headlines focused on drug prices, the Senate Committee on Health, Education, Labor and Pensions is holding a hearing today titled, "The Cost of Prescription Drugs: How the Drug…
Health Plan Use of Patient Data: From the Routine to the Transformational
As the abundance and variety of patient data elements and sources continue to grow, health plans seek opportunities to deepen insights from multiple sources of patient data to shape care delivery,…
Is Real World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Payers infrequently used real-world evidence (RWE), or information on how treatments work in the real world, to guide their medication coverage and reimbursement decisions, according to research…
Do Payers Use Real-World Evidence to Guide Their Coverage and Reimbursement Decisions?
Payers infrequently used real-world evidence (RWE), or information on how treatments work in the real world, to guide their medication coverage and reimbursement decisions, according to new research…
Concerns Around Budget Impact Thresholds: Not All Drugs Are The Same
A study published in Value in Health explores the potential impact of using budget thresholds as budget caps (e.g., cannot spend more than a set dollar amount) for individual drugs.
Data, Data Everywhere, But Access Remains a Big Issue for Researchers
This study captures the policy inconsistencies and hurdles that can hinder use of publicly funded federal and state datasets for researchers. These limitations can make it harder to conduct high…